310 related articles for article (PubMed ID: 27923747)
1. Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage.
Park SS; Jwa E; Shin SH; Ju EJ; Park I; Pak JH; Hwang JJ; Cho DH; Kim BM; Kim SB; Lee JS; Song SY; Jeong SY; Choi EK
Int J Biochem Cell Biol; 2017 Feb; 83():47-55. PubMed ID: 27923747
[TBL] [Abstract][Full Text] [Related]
2. Acetylshikonin Sensitizes Hepatocellular Carcinoma Cells to Apoptosis through ROS-Mediated Caspase Activation.
Hong M; Li J; Li S; M Almutairi M
Cells; 2019 Nov; 8(11):. PubMed ID: 31752383
[TBL] [Abstract][Full Text] [Related]
3. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.
Cho SJ; Kim YJ; Surh YJ; Kim BM; Lee SK
J Biol Chem; 2011 Jun; 286(22):19662-71. PubMed ID: 21478145
[TBL] [Abstract][Full Text] [Related]
4. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
5. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
7. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of TRAIL-mediated apoptosis by anisomycin in human hepatoma cells via the BH3-only protein Bid and c-Jun/AP-1 signaling pathway.
Jin CY; Park C; Hong SH; Han MH; Jeong JW; Xu H; Liu H; Kim GY; Kim WJ; Yoo YH; Choi YH
Biomed Pharmacother; 2013 May; 67(4):321-8. PubMed ID: 23582782
[TBL] [Abstract][Full Text] [Related]
10. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
11. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
Yang JF; Cao JG; Tian L; Liu F
Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
[TBL] [Abstract][Full Text] [Related]
12. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
[TBL] [Abstract][Full Text] [Related]
13. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage.
Jin CY; Park C; Moon SK; Kim GY; Kwon TK; Lee SJ; Kim WJ; Choi YH
Anticancer Drugs; 2009 Sep; 20(8):713-22. PubMed ID: 19617819
[TBL] [Abstract][Full Text] [Related]
14. Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax.
Park SJ; Park SH; Kim JO; Kim JH; Park SJ; Hwang JJ; Jin DH; Jeong SY; Lee SJ; Kim JC; Kim I; Cho DH
Biochem Biophys Res Commun; 2012 Nov; 428(1):185-90. PubMed ID: 23068102
[TBL] [Abstract][Full Text] [Related]
15. Cordycepin increases sensitivity of Hep3B human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by inactivating the JNK signaling pathway.
Lee HH; Jeong JW; Lee JH; Kim GY; Cheong J; Jeong YK; Yoo YH; Choi YH
Oncol Rep; 2013 Sep; 30(3):1257-64. PubMed ID: 23828231
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Ling YH; Lin R; Perez-Soler R
Mol Pharmacol; 2008 Sep; 74(3):793-806. PubMed ID: 18524889
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trautwein C; Michalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Müller M
Cancer Res; 2006 Jul; 66(14):7059-66. PubMed ID: 16849551
[TBL] [Abstract][Full Text] [Related]
19. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
20. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
